Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.49 |
| ▸ | CDK8 | P49336 | 3/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10353678 | 0.91 | PDE3B (0.63) | PDE3BPDE3AHRH3PDGFRBCDK8 | |
| SCHEMBL11116797 | 0.90 | LMNA (0.56) | PDE3BPDE3AHRH3PDGFRBCDK8 | |
| Cadaverine Tartrate SCHEMBL8944439 | 0.87 | PDGFRB (0.49) | PDE3BPDE3AHRH3PDGFRBCDK8 | |
| SCHEMBL11632009 | 0.83 | PDE3B (0.56) | PDE3BPDE3AHRH3PDGFRBCDK8 | |
| SCHEMBL11396639 | 0.83 | HPGD (0.60) | PDE3BPDE3AHRH3PDGFRBCDK8 | |
| SCHEMBL11474002 | 0.83 | PDE3B (0.56) | PDE3BPDE3AHRH3PDGFRBCDK8 | |
| SCHEMBL2844945 | 0.83 | PDE3B (0.56) | PDE3BPDE3AHRH3PDGFRBCDK8 | |
| SCHEMBL8481283 | 0.83 | PDGFRB (0.59) | PDE3BPDE3AHRH3PDGFRBCDK8 | |
| SCHEMBL8898020 | 0.82 | HPGD (0.64) | PDE3BPDE3AHRH3PDGFRBCDK8 | |
| SCHEMBL5678928 | 0.82 | PDE3B (0.56) | PDE3BPDE3AHRH3PDGFRBCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165524-A1 | Process for Preparing Levosimendan and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2012-06-28 | — | — | US | claimed |
| EP-2454241-A1 | PROCESS FOR PREPARING LEVOSIMENDAN AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2012-05-23 | — | — | EP | claimed |
| WO-2011007123-A1 | PROCESS FOR PREPARING LEVOSIMENDAN AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2011-01-20 | — | — | WO | claimed |
| EP-0791584-A1 | OPTICALLY ACTIVE COMPOUND | NIPPON SODA CO., LTD. (JP) | 1997-08-27 | — | — | EP | claimed |
| US-5424428-A | Optical resolution of a drug chemical intermediates 6-(4-amino phenyl)-5-methylpyridazin-3(2H)one by salt-formation with tartaric acid in 2-propanol, desalting by basification | ORION-YHTYMA OY (FI) | 1995-06-13 | — | — | US | claimed |
| EP-0565546-B1 | (-)-[[4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL]-HYDRAZONO]PROPANEDINITRILE | ORION YHTYMAE OY (FI) | 1995-03-08 | — | — | EP | claimed |
| WO-1992012135-A1 | (-)-[[4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL]-HYDRAZONO]PROPANEDINITRILE | Orion-Yhtymä Oy (FI) | 1992-07-23 | — | — | WO | claimed |
| JP-9183767-A | — | — | None | — | — | JP | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| EP-4274576-A1 | PROCESS FOR THE PREPARATION OF HIGH PURITY LEVOSIMENDAN | Navinta, LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11760730-B2 | Process for the preparation of high purity Levosimendan | NAVINTA, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-15 | — | — | US | disclosed |
| EP-0565546-B1 | (-)-[[4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL]-HYDRAZONO]PROPANEDINITRILE | ORION YHTYMAE OY (FI) | 1995-03-08 | — | — | EP | disclosed |
| US-5185332-A | Treating congestive heart failure | ORION-YHTYMA OY (FI) | 1993-02-09 | — | — | US | disclosed |
| WO-1992012135-A1 | (-)-[[4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL]-HYDRAZONO]PROPANEDINITRILE | Orion-Yhtymä Oy (FI) | 1992-07-23 | — | — | WO | disclosed |
| US-5122524-A | Treatment for congestive heart failure; hypertensive agents; vasodilation | ORION-YHTYMA OY (FI) | 1992-06-16 | — | — | US | disclosed |
| US-5019575-A | Congestive Heart Failure Treatment | ORION-YHTYMA OY (FI) | 1991-05-28 | — | — | US | disclosed |
| EP-0383449-A2 | Pyridazinone derivatives and processes for preparing the same | ORION-YHTYMÀ OY (FI) | 1990-08-22 | — | — | EP | disclosed |
| EP-0116853-A1 | Pyridazinones, processes for preparing them, therapeutical compositions containing these compounds and their use | BASF Aktiengesellschaft (DE) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165524-A1 | Process for Preparing Levosimendan and Intermediates for Use in the Process | CYP3A5, HTR5A, CYP2D6 | PDE3B 375/4885PDE3A 220/4885HRH3 2202/4885 |
| US-11760730-B2 | Process for the preparation of high purity Levosimendan | SRD5A2, SRD5A1, TNNC1 | PDE3B 181/4885PDE3A 144/4885HRH3 3651/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | PDE3B 491/4885PDE3A 437/4885HRH3 299/4885 |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | AANAT, NAT1, HNMT | PDE3B 2067/4885PDE3A 2125/4885HRH3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.